ArticleAmerican journal of translational research2017
Triptolide protects podocytes from TGF-β-induced injury by preventing miR-30 downregulation.
Article in American journal of translational research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 13 citations in OpenAlex.
- Triptolide in renal disorders: dual roles of therapeutic potential and nephrotoxicity: a narrative review.Pharmaceutical biology · 2026Review
- Mechanisms of Macrophage Glycolytic Reprogramming and Interventional Effects of Traditional Chinese Medicine on Renal Fibrosis.International journal of general medicine · 2026Review
- Functions and targets of miRNAs in pharmacological and toxicological effects of major components of Tripterygium wilfordii Hook F.Naunyn-Schmiedeberg's archives of pharmacology · 2024Review
- Triptolide Alleviates Podocyte Epithelial-Mesenchymal Transition via Kindlin-2 and EMT-Related TGF-β/Smad Signaling Pathway in Diabetic Kidney Disease.Applied biochemistry and biotechnology · 2022Article
- MicroRNAs as crucial mediators in the pharmacological activities of triptolide (Review).Experimental and therapeutic medicine · 2021Review
- SS31 Ameliorates Podocyte Injury via Inhibiting OMA1-Mediated Hydrolysis of OPA1 in Diabetic Kidney Disease.Frontiers in pharmacology · 2021Article
- miR-30a-5p targets Becn1 to ameliorate high-glucose-induced glomerular podocyte injury in immortalized rat podocyte cell line.American journal of translational research · 2021Article
- miR-30 inhibits proliferation of trophoblasts in preeclampsia rats partially related to MAPK/ERK pathway.Experimental and therapeutic medicine · 2020Article
- Immunomodulatory and Regenerative Effects of Mesenchymal Stem Cell-Derived Extracellular Vesicles in Renal Diseases.International journal of molecular sciences · 2020Review
- The microRNA in ventricular remodeling: the miR-30 family.Bioscience reports · 2019Review
- MicroRNA-30e inhibits adhesion, migration, invasion and cell cycle progression of prostate cancer cells via inhibition of the activation of the MAPK signaling pathway by downregulating CHRM3.International journal of oncology · 2019Article
- Triptolide protects podocytes via autophagy in immunoglobulin A nephropathy.Experimental and therapeutic medicine · 2018Article
- Triptolide inhibits benign prostatic epithelium viability and migration and induces apoptosis via upregulation of microRNA-218.International journal of immunopathology and pharmacologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Triptolide is known to have a strong anti-proteinuric effect through direct protection of podocytes from injury and is used to treat glomerular diseases. However, the mechanism underlying its protective effect on podocytes remains elusive. MiR-30 family has recently been shown to be essential for structural and functional homeostasis of podocytes but is downregulated by injurious factors, leading to podocyte injury. In the present study, we explore whether Triptolide protects podocytes through preventing miR-30 downregulation. Since TGF-β signaling is a critical mediator in various podocyte injuries and we previously found that TGF-β induces podocyte injury through downregulating miR-30s, we thus used TGF-β-induced podocyte injury model to address the issue. We found that Triptolide is capable of protecting cultured podocytes from TGF-β-induced cytoskeletal injury and apoptosis, as expected. Consistently, Triptolide also prevented TGF-β-induced signaling activation of MAPK p38, NFkB (p65) and calcineurin/NFATC3, which are known to be downstream mediators of podocyte injury. Meanwhile, Triptolide was found to completely prevent TGF-β-induced miR-30 downregulation, indicating that Triptolide protects podocytes by sustaining miR-30 expression. Mechanistically, we found that Triptolide can prevent TGF-β-induced Smad2/3 phosphorylation/activation, which likely underlies miR-30 restoration by Triptolide. We also performed
Indexed as
Identifiers
29218112PMC5714798W2991519018What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.